Pharmaceutical Plant Projects Europe · 7d ago

Orexo and SVF Vaccines Partner on AmorphOX-Based LNP-mRNA Vaccine Research in Sweden

Orexo and SVF Vaccines collaborate to explore AmorphOX® powder formulation of LNP-mRNA vaccines, aiming to improve stability, storage, and needle-free intr

RD

Research Desk

· 3 min read

Orexo and SVF Vaccines Partner on AmorphOX-Based LNP-mRNA Vaccine Research in Sweden

Orexo AB (publ.) (STO: ORX) (OTCQX: ORXOY) and SVF Vaccines AB have announced a research collaboration to investigate whether Orexo's proprietary powder-based drug delivery technology, AmorphOX, can be used to develop stable powder-based formulations of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines.

Orexo and SVF Vaccines Evaluate AmorphOX for LNP-mRNA Formulations

The collaboration will assess whether LNP-mRNA formulations can be formulated and spray dried using AmorphOX while preserving critical nanoparticle properties and functional mRNA activity.

The project combines Orexo's expertise in powder formulation and intranasal drug delivery with SVF Vaccines' expertise in vaccine development.

Addressing Stability Challenges in mRNA Vaccines

According to the companies, lipid nanoparticles protect mRNA and enable its delivery into cells. However, maintaining the stability of both the mRNA and its lipid carrier presents formulation challenges that can complicate storage and distribution.

LNP-mRNA formulations often require cold-chain storage and transportation, and stable powder-based formulations could reduce these requirements, simplify handling and distribution, and help broaden access to future mRNA-based products.

If successful, the initial program could support further development of powder-based mRNA vaccines with improved storage, distribution and handling characteristics, including potential needle-free intranasal applications.

The companies noted that further development toward intranasal administration would require additional evaluation of delivery performance, tolerability, and mucosal immune responses.

Statements from Both Companies

"This collaboration will explore whether AmorphOX can address an important formulation challenge in mRNA vaccine development," said Nikolaj Sørensen, President and CEO at Orexo AB. "Our initial objective is to establish whether we can develop stable powder-based formulations while preserving LNP integrity and mRNA activity. Positive results would provide a foundation for further development and help us assess the potential of our technology in vaccines and other biologic applications."

Matti Sällberg, Founder and Chief Scientific Officer of SVF Vaccines, commented, "The clinical success of mRNA vaccines has highlighted both the enormous promise and the formulation challenges associated with these technologies. The ability to convert LNP-mRNA formulations into a stable dry powder suitable for nasal administration could represent an important advancement for the field. Intranasal vaccination offers an opportunity to generate immunity where respiratory pathogens enter the body. This collaboration is an important first step toward exploring how our mRNA vaccine expertise and Orexo's formulation capabilities could support that goal."

Part of Orexo's Broader AmorphOX Strategy

The collaboration forms part of Orexo's strategy to evaluate AmorphOX across additional therapeutic areas and molecule classes.

Results from the initial feasibility program will inform decisions on subsequent development and potential expansion of the collaboration.

Background on the Technology and the Companies

Messenger RNA carries instructions that cells use to produce proteins.

In vaccines, mRNA instructs cells to produce an antigen that helps the immune system recognize and respond to a specific pathogen. Lipid nanoparticles are tiny particles made from lipids that protect mRNA from degradation and facilitate its delivery into cells, making them a key component of mRNA vaccines and therapeutics.

SVF Vaccines is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines and immunotherapies targeting serious viral infections.

The company's pipeline is built on proprietary antigen design strategies that aim to induce both potent neutralizing antibody responses and durable T-cell immunity, supported by expertise in immunology, virology, and translational medicine.

Orexo is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications. At the core of its innovation is AmorphOX, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules.

With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company is headquartered in Uppsala, Sweden, is listed on Nasdaq Stockholm's main market, and trades as ADRs on the OTCQX market in the United States.

Tracked in the database

Pharmaceutical Plant Projects · Europe

Category

Pharmaceutical Plant Projects

Region

Europe

Industry

Chemical

Published

11 November 2026

Length

3 min read

Tagged

mRNA vaccinesdrug formulationintranasal deliveryresearch collaboration

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning